Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 1
1981 1
1984 1
1989 1
1990 1
1995 1
1996 1
1997 1
1998 2
2003 1
2004 4
2005 1
2006 3
2007 1
2008 1
2009 5
2010 6
2011 3
2012 1
2013 1
2014 2
2016 1
2017 1
2018 4
2019 1
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Impaired ADP-induced platelet aggregation"
Page 1
Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y(12) and Link to Residual Platelet Reactivity.
Brambilla M, Becchetti A, Rovati GE, Cosentino N, Conti M, Canzano P, Giesen PLA, Loffreda A, Bonomi A, Cattaneo M, De Candia E, Podda GM, Trabattoni D, Werba PJ, Campodonico J, Pinna C, Marenzi G, Tremoli E, Camera M. Brambilla M, et al. Arterioscler Thromb Vasc Biol. 2023 Oct;43(10):2042-2057. doi: 10.1161/ATVBAHA.123.319099. Epub 2023 Aug 17. Arterioscler Thromb Vasc Biol. 2023. PMID: 37589138 Free PMC article.
BACKGROUND: ADP-induced platelet activation leads to cell surface expression of several proteins, including TF (tissue factor). ...Finally, colchicine impaired in vitro ADP-induced TF expression but not alpha-granule release, suggesting t …
BACKGROUND: ADP-induced platelet activation leads to cell surface expression of several proteins, including TF (tissue …
Is platelet responsiveness to clopidogrel attenuated in overweight or obese patients and why? A reverse translational study in mice.
Jiang LP, Ji JZ, Ge PX, Zhu T, Mi QY, Tai T, Li YF, Xie HG. Jiang LP, et al. Br J Pharmacol. 2022 Jan;179(1):46-64. doi: 10.1111/bph.15667. Epub 2021 Oct 29. Br J Pharmacol. 2022. PMID: 34415054 Free article.
EXPERIMENTAL APPROACH: A post hoc stratified analysis of an observational clinical study was performed to investigate changes in residual platelet reactivity with increasing body weight in patients taking clopidogrel. Furthermore, high-fat diet-induced obese mice we …
EXPERIMENTAL APPROACH: A post hoc stratified analysis of an observational clinical study was performed to investigate changes in resi …
ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Schäfer A, Weinberger S, Flierl U, Eigenthaler M, Störk S, Walter U, Ertl G, Bauersachs J. Schäfer A, et al. Thromb Haemost. 2008 Oct;100(4):618-25. Thromb Haemost. 2008. PMID: 18841284 Clinical Trial.
One hundred consecutive patients with coronary artery disease (CAD) on combined acetylsalicylic acid and clopidogrel treatment (75 mg/d) and 33 patients on aspirin only were screened for platelet ADP-induced signalling by conventional aggregometry, platele …
One hundred consecutive patients with coronary artery disease (CAD) on combined acetylsalicylic acid and clopidogrel treatment (75 mg/d) and …
Glucocorticoids impair platelet thromboxane biosynthesis in community-acquired pneumonia.
Cangemi R, Carnevale R, Nocella C, Calvieri C, Cammisotto V, Novo M, Castellani V, D'Amico A, Zerbinati C, Stefanini L, Violi F; SIXTUS Study Group. Cangemi R, et al. Pharmacol Res. 2018 May;131:66-74. doi: 10.1016/j.phrs.2018.03.014. Epub 2018 Mar 22. Pharmacol Res. 2018. PMID: 29577968
In vitro, glucocorticoids-treated platelets showed a dose-dependent decrease of ADP-induced platelet aggregation, TxB(2) production, cPLA(2) phosphorylation and arachidonic acid release from the platelet membrane. ...Glucocorticoids reduce pl …
In vitro, glucocorticoids-treated platelets showed a dose-dependent decrease of ADP-induced platelet aggregation …
The platelet in diabetes: focus on prevention of ischemic events.
Colwell JA, Nesto RW. Colwell JA, et al. Diabetes Care. 2003 Jul;26(7):2181-8. doi: 10.2337/diacare.26.7.2181. Diabetes Care. 2003. PMID: 12832332 Review.
Accelerated atherosclerosis and the increased risk of thrombotic vascular events in diabetes may result from dyslipidemia, endothelial dysfunction, platelet hyperreactivity, an impaired fibrinolytic balance, and abnormal blood flow. ...Aspirin in low doses inhibits …
Accelerated atherosclerosis and the increased risk of thrombotic vascular events in diabetes may result from dyslipidemia, endothelial dysfu …
Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel.
Mangiacapra F, Pellicano M, Di Serafino L, Bressi E, Peace AJ, Di Gioia G, Morisco C, Bartunek J, Wijns W, Bruyne B, Barbato E. Mangiacapra F, et al. Atherosclerosis. 2018 Nov;278:23-28. doi: 10.1016/j.atherosclerosis.2018.08.044. Epub 2018 Aug 30. Atherosclerosis. 2018. PMID: 30236867 Clinical Trial.
BACKGROUND AND AIMS: Increased platelet reactivity (PR) associated with variable degree of coronary microvascular impairment has been reported in patients on clopidogrel after elective percutaneous coronary intervention (PCI). ...RESULTS: ADP-induced P …
BACKGROUND AND AIMS: Increased platelet reactivity (PR) associated with variable degree of coronary microvascular impairment h …
STIM1, Orai1 and hTRPC1 are important for thrombin- and ADP-induced aggregation in human platelets.
Galán C, Zbidi H, Bartegi A, Salido GM, Rosado JA. Galán C, et al. Arch Biochem Biophys. 2009 Oct 15;490(2):137-44. doi: 10.1016/j.abb.2009.08.007. Epub 2009 Aug 18. Arch Biochem Biophys. 2009. PMID: 19695217
Introduction of an anti-Orai1 (288-301) antibody, which binds the STIM1-binding site located in the Orai1 C-terminus, or extracellular application of anti-hTRPC1 (557-571) antibody to impair hTRPC1 channel function, significantly reduced thrombin- and ADP-induced …
Introduction of an anti-Orai1 (288-301) antibody, which binds the STIM1-binding site located in the Orai1 C-terminus, or extracellular appli …
Platelet dysfunction induced by parenteral carbenicillin and ticarcillin. Studies of the dose-response relationship and mechanism of action in dogs.
Johnson GJ, Rao GH, White JG. Johnson GJ, et al. Am J Pathol. 1978 Apr;91(1):85-106. Am J Pathol. 1978. PMID: 645824 Free PMC article.
ADP-induced primary and secondary platelet aggregation was markedly inhibited within 24 to 48 hours in dogs receiving 750 or 1000 mg/kg/24 hr, but maximum impairment of aggregation did not occur until 3 to 5 days in dogs receiving 250 or …
ADP-induced primary and secondary platelet aggregation was markedly inhibited within 24 to 48 hours in dogs rece …
Impaired adenylate cyclase signaling in acute myocardial ischemia: Impact on effectiveness of P2Y(12) receptor antagonists.
Imam H, Nguyen TH, De Caterina R, Nooney VB, Chong CR, Horowitz JD, Chirkov YY. Imam H, et al. Thromb Res. 2019 Sep;181:92-98. doi: 10.1016/j.thromres.2019.07.016. Epub 2019 Jul 23. Thromb Res. 2019. PMID: 31376607
However, P2Y(12) blockade reverses this ADP-induced suppression of the platelet PGI(2)/AC signaling pathway. ...There was a strong correlation between extent of inhibition of platelet aggregation, whether by PGE(1) or Ilt, and the anti-aggregato …
However, P2Y(12) blockade reverses this ADP-induced suppression of the platelet PGI(2)/AC signaling pathway. ...There w …
Detection of clopidogrel resistance using ADP induced aggregometry with specific inhibitor PGE1.
Slavik L, Ulehlova J, Krcova V, Hlusi A, Indrakova J, Hutyra M, Galuszka J, Indrak K. Slavik L, et al. Clin Lab. 2014;60(9):1475-80. doi: 10.7754/clin.lab.2013.131004. Clin Lab. 2014. PMID: 25291943
BACKROUND: Antiaggregation therapy is still the most frequently used approach to prevent thrombotic events in cardiovascular diseases. It has a good clinical effect but increasing evidence shows high residual platelet aggregation activity in a number of patie …
BACKROUND: Antiaggregation therapy is still the most frequently used approach to prevent thrombotic events in cardiovascular diseases. It ha …
45 results